Restoring Antitumor Immunity via PD-1 Blockade After Autologous Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma
Mené sur 66 patients ayant subi une greffe de cellules souches hématopoïétiques pour le traitement d'un lymphome diffus à grandes cellules B, cet essai international de phase II évalue, du point de vie de la survie sans progression, l'efficacité du pidilizumab, un anticorps monoclonal anti PD-1
T-cell activation requires antigenic stimulation of the T-cell receptor in concert with costimulation by other molecules on the cell surface (Fig 1). A major costimulatory mechanism involves interaction of CD28 on the surface of the T cell with B7.1 (CD80) and B7.2 (CD86) on the surface of the antigen-presenting cell. This interaction results in T-cell proliferation and survival via a variety of pathways, including production of interleukin-2, upregulation of the phosphoinositide 3-kinase (PI3K)/Akt pathway, and expression of the antiapoptotic BCL-2 family of proteins...
Journal of Clinical Oncology , commentaire, 2013